TNF Pharmaceuticals Licenses LightSolver's Compute Accelerator Tech for Innovative Therapies.
ByAinvest
Tuesday, Sep 2, 2025 12:49 pm ET1min read
TNFA--
LightSolver, recognized as a 2025 World Economic Forum Technology Pioneer and a sample vendor in Gartner’s 2025 Hype Cycle for Data Center Infrastructure Technologies, has developed the first laser-based processing unit (LPU) designed to outperform quantum and supercomputing technologies. The LPU harnesses light for computation, offering an accelerated method to solve complex problems at the speed of light.
TNF Pharmaceuticals, under the leadership of Executive Chairman Joshua Silverman, has secured exclusive rights to use LightSolver’s LPU technology in cryptocurrency and blockchain applications. The company intends to change its name to reflect this new venture. TNF Pharmaceuticals aims to leverage this technology to create a more sustainable cryptocurrency infrastructure.
The partnership also involves a $7.0 million private placement financing, with TNF’s largest stockholder and other existing stockholders participating in the sale of 7,000 shares of its newly created Series H convertible preferred stock. The transaction is expected to close on or about September 4, 2025, subject to customary closing conditions.
TNF Pharmaceuticals, which focuses on developing novel therapies for age-related diseases, autoimmune, and inflammatory conditions through its MYMD-1 and Supera-CBD platforms, sees this partnership as an opportunity to capitalize on the growing momentum behind photonic computing and the future of cryptocurrency infrastructure. The company believes it has secured first-mover advantages in a burgeoning industry, positioning itself for growth and value creation.
References:
[1] https://www.businesswire.com/news/home/20250902945912/en/TNF-Pharmaceuticals-Secures-Exclusive-Global-Rights-to-Innovative-Light-Speed-Computing-Accelerator-for-Use-in-Cryptocurrency-Applications
TNF Pharmaceuticals has entered into a licensing agreement with LightSolver for their innovative compute accelerator technology. The biopharmaceutical company focuses on developing novel therapies for age-related diseases, autoimmune, and inflammatory conditions through two therapeutic platforms: MYMD-1 and Supera-CBD. MYMD-1 regulates the immune system to control TNF-a, while Supera-CBD is a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy.
TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) has entered into a licensing agreement with LightSolver Ltd. to utilize the company's innovative light-speed computing accelerator technology. This strategic partnership aims to revolutionize cryptocurrency applications by significantly reducing energy costs and enhancing computational efficiency.LightSolver, recognized as a 2025 World Economic Forum Technology Pioneer and a sample vendor in Gartner’s 2025 Hype Cycle for Data Center Infrastructure Technologies, has developed the first laser-based processing unit (LPU) designed to outperform quantum and supercomputing technologies. The LPU harnesses light for computation, offering an accelerated method to solve complex problems at the speed of light.
TNF Pharmaceuticals, under the leadership of Executive Chairman Joshua Silverman, has secured exclusive rights to use LightSolver’s LPU technology in cryptocurrency and blockchain applications. The company intends to change its name to reflect this new venture. TNF Pharmaceuticals aims to leverage this technology to create a more sustainable cryptocurrency infrastructure.
The partnership also involves a $7.0 million private placement financing, with TNF’s largest stockholder and other existing stockholders participating in the sale of 7,000 shares of its newly created Series H convertible preferred stock. The transaction is expected to close on or about September 4, 2025, subject to customary closing conditions.
TNF Pharmaceuticals, which focuses on developing novel therapies for age-related diseases, autoimmune, and inflammatory conditions through its MYMD-1 and Supera-CBD platforms, sees this partnership as an opportunity to capitalize on the growing momentum behind photonic computing and the future of cryptocurrency infrastructure. The company believes it has secured first-mover advantages in a burgeoning industry, positioning itself for growth and value creation.
References:
[1] https://www.businesswire.com/news/home/20250902945912/en/TNF-Pharmaceuticals-Secures-Exclusive-Global-Rights-to-Innovative-Light-Speed-Computing-Accelerator-for-Use-in-Cryptocurrency-Applications
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet